COMPANY
FDA-cleared device company Clinical Phase 2
Location: Santa Cruz, CA · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- FDA FDA 510(k) clearance: Emboliner Embolic Protection System (EPC-03) — K261715, Sep 8, 2026. Applicant at approval: Emboline, Inc. source ↗
- Trial start Phase 2: Protect the Head to Head Study source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05684146 | Protect the Head to Head Study | Phase 2 | Unknown status (ClinicalTrials.gov) | May 4, 2023 | 2024-10 (estimated) |
FDA records (last 2 years)
- FDA 510(k) clearance: Emboliner Embolic Protection System (EPC-03) — K261715, Sep 8, 2026. Applicant at approval: Emboline, Inc. source ↗
Connect
See your connections at Emboline on LinkedIn (search by name, results not checked)LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-12
